Zoetis Reports Fourth Quarter and Full Year 2015 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/31/2026
- Wall Street closes lower as oil prices jump, indexes notch monthly gains
- The Warsh pivot markets didn't expect
- Oil settles up by more than 2.5% as US and Iran resume military attacks
- Energy stocks rally as fresh U.S.-Iran attacks drive oil prices higher
- BofA turns S&P 500 signals from red to yellow: What to buy now
Zoetis' (ZTS) Simparica Should Gain Approval in March - Piper Jaffray
February 17, 2016 8:19 AM ESTDespite reducing Zoetis Inc. (NYSE: ZTS) price target by 9%, Piper Jaffray analyst, Kevin Ellich kept his Outperform rating and sees a near term catalyst as Simparica prepares for launch and Apoquel finds a second API source.
ZTS reported solid Q4 results highlighted by 6% operational growth which included 30% operational growth in U.S. companion animal product sales. Revenue beat Street estimates even with... More
Zoetis (ZTS) Tops Q4 EPS by 4c; Affirms FY16 EPS Guidance
February 16, 2016 7:02 AM ESTZoetis (NYSE: ZTS) reported Q4 EPS of $0.43, $0.04 better than the analyst estimate of $0.39. Revenue for the quarter came in at $1.3 billion versus the consensus estimate of $1.25 billion.
GUIDANCE:
Zoetis sees FY2016 EPS of $1.71-$1.81, versus the consensus of $1.81. Zoetis sees FY2016 revenue of $4.65-4.775 billion, versus the consensus of $4.82 billion.
In 2015, Zoetis continued to affirm our reputation as the global leader in the animal health industry with a strong financial performance, ongoing investments in... More
